IGMS IGM Biosciences Inc - Ordinary Shares

22.72
+1.2  (+6%)
Previous Close 21.52
Open 21.64
Price To Book 2.72
Market Cap 693,775,625
Shares 30,535,899
Volume 207,271
Short Ratio
Av. Daily Volume 108,035
Stock charts supplied by TradingView

NewsSee all news

  1. IGM Biosciences to Present at Three Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of

  2. IGM Biosciences Announces Third Quarter 2019 Financial Results

    MOUNTAIN VIEW, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of

  3. IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

    MOUNTAIN VIEW, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial data due 2H 2020.
IGM-2323
Relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL)

Latest News

  1. IGM Biosciences to Present at Three Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of

  2. IGM Biosciences Announces Third Quarter 2019 Financial Results

    MOUNTAIN VIEW, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of

  3. IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

    MOUNTAIN VIEW, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients,